Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
InoviqBDLSF 27 3-1 Month Momentum % is N/A% as of Jul. 21, 2026. GuruFocus rates BDLSF with a GF Score™ of 27/100 and a GF Value™ of $0.29. The stock has 2 warning signs investors should review. Among 214 Medical Diagnostics & Research companies, Inoviq ranks better than 85.98% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-07-21), Inoviq's 3-1 Month Momentum % is N/A%.
The industry rank for Inoviq's 3-1 Month Momentum % or its related term are showing as below:
BDLSF's 3-1 Month Momentum % is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: -7.105 * Ranked among companies with meaningful 3-1 Month Momentum % only.
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Inoviq 3-1 Month Momentum % Related Terms
BDLSF vs TMO, DHR, IDXX: 3-1 Month Momentum % Comparison
For the Diagnostics & Research subindustry, Inoviq's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Inoviq 3-1 Month Momentum % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Inoviq's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Inoviq's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inoviq (BDLSF) has a 3-1 Month Momentum % of N/A% as of Jul. 21, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Inoviq and its competitors. According to the industry distribution chart, Inoviq ranks #30 out of 214 companies in the Medical Diagnostics & Research industry, placing it in the top 14%.
Is Inoviq's 3-1 Month Momentum % too high?
Inoviq's current 3-1 Month Momentum % is N/A%. Based on the distribution chart, Inoviq ranks #30 out of 214 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Inoviq has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Inoviq's 3-1 Month Momentum % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Inoviq ranks #30 out of 214 companies for 3-1 Month Momentum %. This places Inoviq in the top 14% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Medical Diagnostics & Research company?
A good 3-1 Month Momentum % depends on the Medical Diagnostics & Research industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Inoviq and its competitors. Inoviq's current 3-1 Month Momentum % is N/A%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inoviq stock overvalued right now?
Inoviq (BDLSF) has a current 3-1 Month Momentum % of N/A%. The stock's GF Value™ is $0.29, compared to a current price of $0.12 — trading 58.6% below its estimated fair value. The current 3-1 Month Momentum % is N/A%. Inoviq's overall GF Score™ is 27/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Inoviq (BDLSF), the current 3-1 Month Momentum % is N/A% as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Inoviq (BDLSF) Overvalued in 2026?
Based on GuruFocus' analysis, Inoviq stock appears to be undervalued.
The current stock price of $0.12 is trading 58.6% below its estimated GF Value™ of $0.29.
Key valuation signals for BDLSF:
3-1 Month Momentum %: N/A%
GF Value™: $0.29 vs. price of $0.12 (58.6% below fair value)
No single metric tells the full story. See the BDLSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Inoviq Ltd is engaged in developing and commercializing a portfolio of diagnostic and exosome-based products to improve the diagnosis and treatment of cancer and other diseases. The company has commercialized the hTERT test used as an adjunct to urine cytology testing for bladder cancer and the EXO-NET pan-exosome capture tool for research purposes. Its cancer diagnostic pipeline includes blood tests in development for earlier detection and monitoring of ovarian, breast, prostate, and other cancers. The Group operates predominantly in one business segment, the research and development of cancer diagnostics, and two geographical segments, Victoria, Australia, and the United States of America, with the majority of revenue coming from Australia.
27GF Score
Get the complete analysis for BDLSF
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BDLSF has been successfully added to your 
